AZN catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 31, 2026Sponsor estimate | NCT06147037A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursAstraZeneca · Advanced Solid Tumor | AZNLead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT06147037A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursAstraZeneca · Advanced Solid TumorActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 25, 2027Sponsor estimate | NCT07534592A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy ParticipantsAstraZeneca · Healthy Participants | AZNLead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
| Jan 29, 2027Sponsor estimate | NCT06151964A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With...AstraZeneca · Overweight and Obesity | AZNLead | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Jan 29, 2027Sponsor estimate | NCT07000149A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCAstraZeneca · Advanced Clear Cell Renal Cell Carcinoma | AZNLeadRCUSCollaborator | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 25, 2027Sponsor estimatePhase 1NCT07534592A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy ParticipantsAstraZeneca · Healthy ParticipantsActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2027Sponsor estimatePhase 1/Phase 2NCT06151964A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With...AstraZeneca · Overweight and ObesityActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2027Sponsor estimatePhase 1NCT07000149A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCAstraZeneca · Advanced Clear Cell Renal Cell CarcinomaActive, not recruitingAZNLeadRCUSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.